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Abstract 
[D-Lys3]-Growth Hormone Releasing Peptide-6 (DLS) is widely utilized in vivo and in vitro as a 
selective ghrelin receptor (GHS-R) antagonist. This antagonist is one of the most common 
antagonists utilized in vivo to block GHS-R function and activity.  Here, we found that DLS 
also has the ability to modestly block chemokine function and ligand binding to the chemokine 
receptor CCR5. The DLS effects on RANTES binding and Erk signaling as well as calcium 
mobilization appears to be much stronger than its effects on MIP-1α and MIP-1β.  CCR5 have 
been shown to act as major co-receptor for HIV-1 entry into the CD4 positive host cells. To 
this end, we also found that DLS blocks M-tropic HIV-1 propagation in activated human 
PBMCs. These data demonstrate that DLS may not be a highly selective GHS-R1a inhibitor 
and  may  also  effects  on  other  G-protein  coupled  receptor  (GPCR)  family  members.  
Moreover, DLS may have some potential clinical applications in blocking HIV infectivity and 
CCR5-mediated migration and function in various inflammatory disease states. 
Key words: MIP-1, MIP-1, RANTES, CCR5; HIV-1, Ghrelin, GHRP-6, GHS-R1a, Inflammation, 
Cancer. 
Introduction 
Chemokines are small peptides that are known 
to  exert  potent  regulatory  effects  on  migration  and 
activation of various immune and non hematopoietic 
cells  via  ligation  to  their  seven  transmembrane 
G-protein coupled receptors [1, 2]. CCR5 serves as an 
endogenous  ligand  for  CC  chemokines, 
MIP-1/CCL3,  MIP-1/CCL4  and  RANTES/CCL5. 
CC chemokine receptor 5 (CCR5) regulates trafficking 
and  effector  functions  of  memory/effector 
T-lymphocytes,  macrophages,  and  immature  den-
dritic  cells  [3].  Interestingly,  chemokine  receptors 
CXCR4 and CCR5 have attracted substantial interest 
because  they  form  portals  of  cellular  entry  for  the 
human immunodeficiency viruses (HIV-1 and HIV-2) 
and related simian or feline retroviruses[4]. While all 
the HIV-1 strains require CD4 to enter and infect cells, 
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some  use  the  chemokine  receptor  CXCR4 
(T-tropic/X4  strain  or  syncytium-inducing  viruses), 
or  CCR5  (M-tropic/R5  strain  or 
non-syncytium-inducing  viruses)  and  some  can  uti-
lize either coreceptor (R5X4 strains) for these purpos-
es.  Several HIV-1 coreceptor antagonists have been 
recently discovered and are being utilized in human 
clinical trials[5].  In addition to pathogenesis of HIV, 
CCR5 receptors have been implicated in motility [2]. 
Given the involvement of CCR5 in HIV and inflam-
mation  these  receptors  have  emerged  as  potential 
targets for therapeutic intervention [4]. 
 Growth  hormone  secretagogue  receptor 
(GHS-R)  belongs  to  a  seven  transmembrane  GPCR 
family and serves as an endogenous ligand for stom-
ach derived hormone ghrelin [6, 7]. Growth hormone 
releasing peptide-6 (GHRP-6) is one of earliest syn-
thetic  peptidyl  GHS-R  agonist  utilized  to  study  the 
functions of GHS-R prior to the discovery of the en-
dogenous ligand ghrelin[8]. Modification of GHRP-6 
(H-His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) from alanine 
to  D-lysine  resulted  in  a  GHS-R  antagonist 
D-[Lys3]GHRP-6  (H-His-D-Trp-D-Lys-Trp-D-Phe- 
Lys-NH2).  Currently,  the  D-[Lys3]GHRP-6  (DLS)  is 
utilized in in vitro and in vivo studies as a selective 
GHS-R antagonist[7] (Figure 1). However, no studies 
have yet addressed the specificity and efficacy of this 
compound  in  human  T  lymphocytes,  T  cell  lines, 
PBMCs or other immune cell subsets.  Given the po-
tent effects of natural GHS-R ligand ghrelin on human 
T  cell  responses  [9],  we  evaluated  the  specificity  of 
DLS and its potential interactions with other immu-
nologically relevant GPCRs of chemokine family and 
present evidence that DLS also modestly antagonizes 
CCR5  receptor  signaling,  function  and  HIV-1  core-
ceptor activity. The most important finding in these 
studies if not the discovery of DLS as a potential HIV 
antagonist (as other more potent and selective chem-
okine receptor antagonist are more efficient and se-
lective) but that the DLS antagonist is not as highly 
selective to GHS-R1a as originally thought and may 
have some impact on other G-protein coupled recep-
tors (GPCRs) including chemokine receptors. 
Materials and Methods 
Cell culture and Cell lines 
CEM.NKR-CCR5,  3T3.T4.CCR5,  CCR5  receptor 
antagonist TAK779 [10] and HIV-1Ba-L  [11] were ob-
tained  from  the  AIDS  Research  and  Reference  Rea-
gent  Program,  Division  of  AIDS,  NIAID,  NIH  ( 
CEM.NKR-CCR5  from  Dr.  Alexandra  Trkola, 
3T3.T4.CCR5 from Dr. Dan R. Littman, HIV-1Ba-L from 
Dr.  Suzanne  Gartner,  Dr.  Mikulas  Popovic  and  Dr. 
Robert Gallo). Pheresis packs were prepared from 4 
healthy male donors between 18 and 45 years age for 
the isolation of PBMCs. PBMCs were obtained by Fi-
coll-Hypaque  density  centrifugation.  PBMCs  were 
activated with PHA. 
 
 
 
Figure 1. Structure of DLS.  
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Intracellular calcium mobilization 
Measurement of intracellular calcium release in 
response  to  MIP-1(60nM),  MIP-1  (60nM)  and 
RANTES  (10nM)  were  performed  as  described  pre-
viously  and  as  described  in  the  legends  [12]. 
CEM.NKR-CCR5  cells  were  incubated  in  PBS  con-
taining 5 mM Fura-2 acetoxymethyl ester (Molecular 
Probes) for 30 minutes at room temperature. The cells 
were subsequently washed and then resuspended at 1 
x 106cells per ml in PBS. A total of 2 ml of the cell 
suspension was placed in a continuously stirring cu-
vette  at  room  temperature in  an  LS50B  spectropho-
tometer  (Perkin-Elmer,  Wellesley,  Massachusetts, 
USA). Cells were treated with MIP-1(60nM), MIP-1 
(60nM)and  RANTES  (10nM)  and  along  with  DLS 
(Sigma-Aldrich)  at  various  concentrations.  Fluores-
cence was monitored at λex1 = 340 nm, λex2 = 380 nm, 
and λem = 510 nm. The data are presented as the rela-
tive ratio of fluorescence excited at 340 and 380 nm.  
Fluorokine ligand binding  
Fluorokine binding assay was performed as de-
scribed  previously  and  in  the  Figure  legends  [13].  
Briefly,  biotinylated  MIP-1,  MIP-1β  and  RANTES 
(Fluorokine;  R&D  Systems)  staining  was  performed 
according  to  R&D  Systems’  protocols,  with  slight 
modifications. The control or treated CEM.NKR-CCR5 
cells were resuspended in PBS at 4 x 106cells per ml. 
25l of cells were treated with 1g, 4g or 16 g of 
DLS at 37°C for 30 min, then mixed with 20 µl of 2.5 
µg/ml biotinylated SDF-1 and incubated at 4°C for 1 
h. 20l fluorescein-conjugated avidin (10 µg/ml) was 
added to the cells and incubated for an additional 30 
min at 4°C. After incubation, cells were washed with 
1x RDF-1 buffer (R&D Systems) and then fixed with 
2% paraformaldehyde in PBS before being analyzed 
on a FACScan (BD Biosciences).  
Western blot analysis 
As  described  here  and  in  the  Figure  legends, 
control and treated 3T3.T4.CCR5 cells were lysed in 
RIPA buffer supplemented with protease and phos-
phatase  inhibitor  cocktail  (Sigma-Aldrich,  St.  Louis, 
MO) and protein concentrations of cell lysates were 
determined by Bradford assay. Protein lysates (30g) 
were  diluted  with  sample  buffer  and  separated  on 
4-20%  Tris  HCl  SDS-polyacrylamide  gels  (Biorad, 
Hercules, CA) and electrophoretically transferred to 
nitrocellulose membranes (Schleicher & Schuell). The 
blots  were  then  incubated  with  rabbit  an-
ti-phospho-P42  and  pERK  (Cell  Signaling,  Beverly, 
MA). Immune complexes were visualized by incuba-
tion  with  either  an  anti-rabbit  or  an  anti-mouse 
HRP-conjugated  secondary  antibody  (Amersham, 
Piscataway, NJ). The immunoreactive band was visu-
alized  by  enhanced  chemiluminescence  (Per-
kin-Elmer). 
HIV infection 
HIV-1Ba-L  was  propagated  in  activated  PBMC 
cells and p24 was measured in sup by ELISA (SAIC, 
Frederick,  USA).  PBMCs were  activated  by  5g/ml 
phytoheamagglutinin (PHA) and 10units/ml IL2 for 
three days, on day three, cells were washed and re-
suspended as one million per ml in cRPMI medium. 
Activated PBMCs were treated with various concen-
trations of DLS and TAK779 at 37C for 30 minutes. 
Then HIV-1Ba-L was added to a final concentration of 
p24 of 10ng/ml. Incubate at 37C for three hours and 
wash cells to remove virus, resuspend cells as 5e+5 
cells per ml, add antagonist and  plate as triplicates in 
24 well plate. Collect sup at day 3, 6 and 9 and meas-
ure p24 level in sup by ELISA. Graphs show % of p24 
level over virus only controls at day 6 and day 9.  
  
Results 
D-Lys3-GHRP-6 inhibits MIP-1, MIP-1 and 
RANTES induced intracellular calcium release 
from CEM.NKR-CCR5 cells 
Ligation  of  seven  transmembrane  GPCRs  typi-
cally results in  calcium mobilization from the intra-
cellular stores by generation of inositol triphosphate. 
MIP-1,  MIP-1  and  RANTES  binding  to  CCR5  is 
known to elicit a potent release of calcium from in-
tracellular  sources.  The  direct  effects  of  DLS  on 
MIP-1, MIP-1 and RANTES induced calcium mobi-
lization were evaluated on CEM.NKR-CCR5 cells la-
beled  with  Fura-2AM.  MIP-1(60nM),  MIP-1 
(60nM)and RANTES (10nM) caused a significant in-
crease in intracellular calcium and this calcium flux 
was markedly inhibited in a dose dependent fashion 
by DLS (Figure 2). DLS inhibition of calcium release 
was  seen  more  clearly  with  RANTES  than  with 
MIP-1 and MIP-1. Interestingly, higher concentra-
tions of DLS were typically needed to observe a re-
producible effect on chemokine-induced intracellular 
calcium  mobilization.  TAK779  was  able  to  almost 
completely block the binding of all three chemokines 
at  concentrations  less  than  2  µM  (data  not  shown), 
demonstrating TAK779 to be a much more potent and 
selective antagonist than the GHS-R1a antagonist be-
ing examined here.   
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Figure 2. D-Lys3-GHRP-6 inhibits SDF-1-, MIP-1α-, MIP-1- and RANTES-induced intracellular calcium release from CEM-CCR5 cells.  
CEM-CCR5 cells were loaded with Fura-2-AM dye, washed, treated with different concentration of DLS for 20 minutes and 1.5 ml 
cells  used  to  read  for  calcium  release  after  addition  of  chemokine  in  luminescence  spectrometer.  Each  graph  shows  the 
340nm/380nm excitation ratio at 509nm absorption. It shows CEM-CCR5 cells’ calcium release after addition of MIP-1β (60nM), 
MIP-1α (60nM) and RANTES (10nM). The data reveals that, DLS partially inhibits MIP1, MIP1 and RANTES induced calcium 
release (range of 10-40% inhibition). 
 
 
DLS inhibits MIP-1α, MIP-1 and RANTES 
binding 
To determine if DLS blocks CCR5 receptor, we 
utilized a whole cell ligand binding assay with a bio-
tinylated form of MIP-1, MIP-1 and RANTES, fol-
lowed by binding of an avidin-fluorescein isothiocy-
anate (FITC) conjugate, and subsequent examination 
by  using  flow  cytometric analysis.  Upon  DLS  treat-
ment  the  percent  maximal  binding  of  MIP-1  and 
RANTES  in  the  CEM.NKR-CCR5  cells  was  reduced 
reproducibly by up to 40% in the donors tested but 
binding  of  MIP-1  was  not  dramatically  affected 
(Figure  3)  suggesting  that  DLS  may  differentially 
blocks chemokine ligand binding to the CCR5 recep-
tor.  As expected, TAK779 was able to almost com-
pletely block the binding of all three chemokines at 
concentrations  less  than  2µM  (data  not  shown), 
demonstrating TAK779 to be a much more potent and 
selective antagonist than the GHS-R1a antagonist be-
ing examined here.  
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Figure 3.  DLS selectively blocks chemokine ligand binding to receptor-positive cells.  25lof 4 million/ml cells were incubated with or 
without different amount of DLS (1/4/16g) or TAK779 (for CCR5 inhibition, 1g) for 30 minutes at 4°C. Add 20 ml of bioti-
nylated-chemokine and incubate for 1hr at 4°C. After incubation, 20 l of avidin-fluoresceine was added to the wells and then the 
plate was incubated for 30 minutes at 4°C. The cells were subsequently washed with 1xRDF b/f. Fix cells with 2% PFA and run on 
FACScan. Graph shows fluorescence intensity for each treatment. Results reveal that, DLS blocks binding of MIP-1 and RANTES 
with 20%-40% range. DLS does not affect MIP-1 binding.   
DLS inhibits chemokine-mediated signaling in 
CCR5-transfected 3T3 cell lines   
3T3.T4.CCR5  cells  were  grown  overnight  and 
then pretreated with DLS (20M) or the CCR5 specific 
antagonist, TAK779 (2M) for 30 minutes at 37°C after 
which  10nM  of  MIP-1β  or  RANTES  were  added  to 
cultures. The cells harvested in RIPA after washing 
with  cold  PBS  at  the  indicated  times.    The  results 
(Figure  4)  reveal  that  DLS  partially  blocks 
RANTES-induced  ERK  activation  in  3T3.T4.CCR5 
cells.    Surprisingly,  MIP-1β-induced  ERK  activation 
was not influenced by DLS using this cell line. Tak779 
at 2µM only demonstrated a 20-30% inhibition of ERK 
phosphorylation in these CCR5 expressing cells. 
DLS decreases HIV-1 propagation in vitro in 
activated PBMCs  
Given  the  ability  of  DLS  to  partially  abrogate 
chemokine binding and signaling, we sought to de-
termine if DLS could exhibit any inhibitory effects in 
HIV-1 infectivity in human PBMCs. Activated PBMCs 
treated with DLS or the chemokine receptor antago-
nist TAK779 for 30 minutes at 37°C. HIV-1Ba-L (CCR5 
tropic) was added to the cultures at 37°C for 3 hours. 
The non-bound virus was washed off the treated cells 
and the cells were cultured for 3, 6 or 9 days to ex-
amine HIV-1Ba-L viral output by the infected cells. Su-
pernatants were collected from each well at day 3, 6 
and  9  and  p24  levels  were  measured  using  ELISA 
assays. The results reveal that DLS inhibits R5 tropic 
HIV-1Ba-L propagation in PBMCs (Figure 5).  Int. J. Med. Sci. 2012, 9 
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Figure 4.  DLS inhibits chemokine- mediated signaling in CCR5-transfected 3T3 cell lines.  Approximately 200,000 3T3.T4.CCR5 cells 
were grown overnight per well in 6-well plate. On the following day, the media was replaced with 2ml of serum free medium. After 
2-3 hrs, DLS (20M) or the CCR5 specific antagonist, TAK779 (2M), were added to respective wells, incubated for 30 minutes at 
37°C after which 10nM of  RANTES (A) or MIP-1β (B) was added to indicated wells. The cells harvested in RIPA after washing with 
cold PBS at the indicated times. 30g of protein run in 4-20% Bis-Tris gel, transferred and probed with mouse anti-pERK antibody 
(upper panel) stripped and again probed with rabbit anti-total ERK antibody (lower panel).  The results reveal that DLS partially 
blocks RANTES induced ERK activation but surprisingly does not block MIP-1β-induced ERK activation in 3T3.T4.CCR5 cells.  
 
 
 
 
 
Figure  5.  DLS decreases HIV-1 propagation in vitro in 
activated PBMCs.  Activated  PBMCs  were  washed  and 
treated with DLS or TAK779 for 30 minutes at 37°C. 
Add  10ng  (p24)  of  HIV-1Ba-L  (CCR5  tropic)  per  one 
million cells in one ml medium , incubate at 37°C for 
3hrs. Wash cells to remove unbound virus and resus-
pended to a concentration of 0.5 million cells per one ml 
medium, add antagonists and plate in triplicate wells in 
24-well plate and incubate at 37°C. Collect supernatant 
from each well at day 6 and 9 and measure p24 level 
using ELISA. The graphs show % of p24 level over virus 
only controls at day 6 & 9. The results reveal that DLS 
inhibits R5 tropic HIV-1 propagation in PBMCs. 
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Discussion 
Migration of immune cells to sites of inflamma-
tion is a multistep process mediated largely by inter-
actions  of  various  chemokines  to  their  G  protein 
linked seven transmembrane receptors [1, 14]. CCR5 
and  CXCR4  are  the  principal  chemokine  receptors 
critical for cellular migration and are used in associa-
tion  with  CD4  by  human  immunodeficiency  virus 
(HIV) to enter its target cells. These co-receptors are 
important determinants of viral tropism, pathogenesis 
and virulence and are widely believed to be important 
drug targets to prevent HIV infections [4]. A number 
of  CCR5  inhibitors  like  SCH417690,  UK427857, 
GSK873140,  PRO140  are  currently  being  tested  for 
their efficacy against R5 tropic HIV viruses [10]. The 
synthetic  peptidyl  compound  D-[Lys3]GHRP-6 
(H-His-D-Trp-D-Lys-Trp-D-Phe-Lys-NH2)  is  cur-
rently believed to be a selective antagonist of ghrelin 
receptors (GHS-R). However, no studies exist on the 
potential  interaction  of  this  compound  with  other 
clinically  relevant  GPCRs  of  chemokine  family.  We 
have discovered that DLS can also modestly antago-
nize the binding and signaling  of CCR5 chemokine 
receptor,  more  potently  acting  on  RANTES  activity 
through CCR5  (Figure 6). DLS has been utilized ex-
perimentally in rodent models without any adverse 
side  effects  and  repeated  administration  have  been 
found to reduce body weight in obese mice and im-
prove their glycaemic control and insulin resistance 
[15]. Furthermore, DLS reduced the size of abdominal 
fat pads without affecting the muscle mass in these 
mice. There is accumulating clinical evidence linking 
currently used HIV inhibitors to the pathogenesis of 
insulin  resistance,  dyslipidemia,  lipodystrophy  and 
atherosclerosis in AIDS patients [16].  Thus DLS along 
with its potential HIV inhibitory properties may at-
tenuate the metabolic effects associated with HAART 
therapy in AIDS patients. Additionally, DLS does not 
affect  food  intake  in  the  fed  state  when  circulating 
ghrelin levels are low, allowing for its potential use 
post-prandially. 
 
 
Figure 6.  Summary of DLS and TAK779 activities on HIV-1 propagation and CCR5 Function.  While the current and most efficient 
treatment modalities for the treatment of HIV-1+ patients include reverse transcriptase and protease inhibitors, viruses are now 
developing resistance to one or more agents. Despite the efficacy of these agents, there is still dire need to discover new anti-HIV 
agents to inhibit viral infectivity. CXCR4 and CCR5 are the major co-receptors for HIV-1 entry into the CD4 positive cells. Thus, 
it would appear that chemokine receptors, more specifically here CCR5, are attractive targets to block HIV-1 binding, fusion and 
infectivity. Several potent chemokine receptor antagonists have been developed and are being utilized in clinical studies.  TAK779 
is a very selective CCR5 blocking agent and has been shown to block HIV-1 entry through CCR5-bearing cells and also blocks 
CCR5 function and signaling. We have found that the GHS-R1a antagonist, DLS, exhibits some modest blocking effects on CCR5 
ligand binding and signaling, with the greatest effects being observed on RANTES binding and activity.  Moreover, DLS can inhibit 
CCR5-trophic HIV-1 infectivity in CCR5+ immune cells, although it is significantly less potent than the CCR5 selective antagonist, 
TAK779, which is currently being utilized in clinical trials.  While DLS may possess some modest antagonist activity for CCR5, the 
primary finding focused on in this manuscript is that DLS, initially thought to be a highly selective antagonist for the ghrelin re-
ceptor, GHS-R1a, appears to be promiscuous and may have some effects on other G-protein coupled receptors (GPCRs) such as 
chemokine receptors. Int. J. Med. Sci. 2012, 9 
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Therapy  for  HIV-1+  subjects  includes  reverse 
transcriptase and protease inhibitors. These inhibitors 
have achieved sustained suppression of viral replica-
tion  in  HIV-1-infected  individuals,  although  these 
viruses are now developing resistance to one or more 
agents. These inhibitors are costly and require long 
term use.  Despite the efficacy of these agents, there is 
still dire need to discover new anti-HIV agents to in-
hibit viral infectivity. CXCR4 and CCR5 are the major 
co-receptors  for  HIV-1  entry  into  the  CD4  positive 
cells.  Several  of  the  SNPs  and  specific  deletions  in 
CXCR4 and CCR5 genes have been shown to result in 
a resistance or slower progression of HIV-1 infection 
without any substantial immune (functional) defect in 
humans.  Thus,  it  would  appear  that  chemokine  re-
ceptors, more specifically CXCR4 and CCR5, are at-
tractive  targets  to  block  HIV-1  binding,  fusion  and 
infectivity (Figure 6). TAK779 is a very selective CCR5 
[10] blocking agent. Surprisingly, this antagonist has 
been discontinued after phase I trial, because of severe 
toxicities [5].  
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